Skip to main content


New oral medication may become tool against malaria

Sotrastaurin targets a specific enzyme to halt deadly spread of disease


Genetic research into how malaria enters and infects the human body has paved the way for a new oral medication that can now stop the deadly mosquito-borne disease in its tracks. Sotrastaurin, a drug that's already in clinical trials for use against another condition, may now become the frontline in battling a disease that has long plagued developing nations.

In tracking the progression of the disease, researchers learned that the malaria-infected female Anopheles mosquito injects about 1,000 parasites into the human bloodstream.

In tracking the progression of the disease, researchers learned that the malaria-infected female Anopheles mosquito injects about 1,000 parasites into the human bloodstream.

LOS ANGELES, CA (Catholic Online) - Researchers say they have discovered how the malaria parasite gains a foothold inside the human body. In tracking the progression of the disease, researchers learned that the malaria-infected female Anopheles mosquito injects about 1,000 parasites into the human bloodstream.
 
The microorganisms quickly reproduce after each one enters a red blood cell.

"Each parasite divides from one into say 24 to 32 parasites in 48 hours. So you can imagine that an initial thousand parasites can grow very fast," Doron Greenbaum, a professor of pharmacology at the University of Pennsylvania says.

Greenbaum and his colleagues discovered that inside the red blood cells, the parasites utilize a series of proteins to reproduce.

After robbing the cells of their nutrient machinery, the newborn parasites burst through the cell walls and back into the blood stream. It is here that they infect new blood cells, producing millions more offspring. After a one to two-week incubation period, the parasitic infection causes the often fatal symptoms associated with malaria. These commonly include high fevers, chills and sweats.

The malaria pathogen targets a particular enzyme called PKC, which weakens the protein chain, dismantling the cells and causing them to collapse. Sotrastaurin blocks P. falciparum's interaction with PKC.

Without that interactionthe parasites can't reproduce. "They are sort of trapped inside the host cell and if they can't get out, they can't continue their lifecycle and within a couple of hours, they start to die," Greenbaum said.

Greenbaum's team tested the experimental drug, now in clinical trials to prevent organ rejection in transplant patients. It was found that the compound dramatically reduced the number of P. falciparum malaria parasites in infected laboratory mice.
 
Because sotrastaurin targets human cellular proteins, Greenbaum says P. falciparum can't develop resistance to the drug which has made quinine and artemisinin drugs to treat malaria less effective in recent years.

© 2013, Distributed by NEWS CONSORTIUM.

- - -

Pope Benedict XVI's Prayer Intentions for January 2013
General Intention:
The Faith of Christians. That in this Year of Faith Christians may deepen their knowledge of the mystery of Christ and witness joyfully to the gift of faith in him.
Missionary Intention: Middle Eastern Christians. That the Christian communities of the Middle East, often discriminated against, may receive from the Holy Spirit the strength of fidelity and perseverance.

Keywords: Malaria, genetics, female mosquitos, Sotrastaurin

NEWSLETTERS »

E-mail:       Zip Code: (ex. 90001)
Today's Headlines

Sign up for a roundup of the day's top stories. 5 days / week. See Sample

Rate This Article

Very Helpful Somewhat Helpful Not Helpful at All

Yes, I am Interested No, I am not Interested

Rate Article

1 - 1 of 1 Comments

  1. Dr.Akusa Yuma Darlington
    4 months ago

    I have interest in your work on malaria targeting PKC.because i am involved in a similar work but using antihistamine, which through PfTCTP, IP3 and DG elaboration increases PKC production resulting in lack of immunity to Malaria.

    My experience with this antihistamine use in combination with antimalarial over a period of 12 years now shows that it offers cure and long term immunity to malaria for a period of more than seven years.

    In absence of a vaccine for malaria at the moment, this could be a solution to malaria.

    I am willing to join your researchers to prove my hypothesis.

    Best regards,

    Dr. Akusa Yuma Darlington,

    Arua Regional Referral Hospital,
    P.O Box 3,
    Arua,
    Uganda

Leave a Comment

Comments submitted must be civil, remain on-topic and not violate any laws including copyright. We reserve the right to delete any comments which are abusive, inappropriate or not constructive to the discussion.

Though we invite robust discussion, we reserve the right to not publish any comment which denigrates the human person, undermines marriage and the family, or advocates for positions which openly oppose the teaching of the Catholic Church.

This is a supervised forum and the Editors of Catholic Online retain the right to direct it.

We also reserve the right to block any commenter for repeated violations. Your email address is required to post, but it will not be published on the site.

We ask that you NOT post your comment more than once. Catholic Online is growing and our ability to review all comments sometimes results in a delay in their publication.

Send me important information from Catholic Online and it's partners. See Sample

Post Comment


Newsletter Sign Up